TR200201642T2 - Prokollajen C-Proteinaz inhibitörleri olarak yararlı olan OX (ADI) azolil-hidroksamik asitler. - Google Patents

Prokollajen C-Proteinaz inhibitörleri olarak yararlı olan OX (ADI) azolil-hidroksamik asitler.

Info

Publication number
TR200201642T2
TR200201642T2 TR2002/01642T TR200201642T TR200201642T2 TR 200201642 T2 TR200201642 T2 TR 200201642T2 TR 2002/01642 T TR2002/01642 T TR 2002/01642T TR 200201642 T TR200201642 T TR 200201642T TR 200201642 T2 TR200201642 T2 TR 200201642T2
Authority
TR
Turkey
Prior art keywords
procollagen
proteinase
inhibitors
azolyl
adi
Prior art date
Application number
TR2002/01642T
Other languages
English (en)
Inventor
Bailey Simon
Billotte Stephane
Michael Derrick Andrew
Vincent Fish Paul
James Kim
Murray Thomson Nicholas
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200201642T2 publication Critical patent/TR200201642T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ikame maddelerinin degerlerinin burada verildigi formül (I) bilesikleri ve bunlarin tuzlari, çözünür maddeleri, ön ilaçlari ve benzeri bilesikler Prokollajen C-Proteinaz (PCP) inhibitörleridir ve PCP'nin araci rol oynadigi rahatsizliklarda kullanilirlar.
TR2002/01642T 1999-12-23 2000-12-12 Prokollajen C-Proteinaz inhibitörleri olarak yararlı olan OX (ADI) azolil-hidroksamik asitler. TR200201642T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930570.8A GB9930570D0 (en) 1999-12-23 1999-12-23 Therapy

Publications (1)

Publication Number Publication Date
TR200201642T2 true TR200201642T2 (tr) 2002-11-21

Family

ID=10866986

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01642T TR200201642T2 (tr) 1999-12-23 2000-12-12 Prokollajen C-Proteinaz inhibitörleri olarak yararlı olan OX (ADI) azolil-hidroksamik asitler.

Country Status (32)

Country Link
EP (1) EP1240152B1 (tr)
JP (1) JP2003519133A (tr)
KR (1) KR20020067570A (tr)
CN (1) CN1423638A (tr)
AP (1) AP2002002554A0 (tr)
AR (1) AR031085A1 (tr)
AT (1) ATE284393T1 (tr)
AU (1) AU1875601A (tr)
BG (1) BG106866A (tr)
BR (1) BR0016717A (tr)
CA (1) CA2395186C (tr)
CO (1) CO5261622A1 (tr)
DE (1) DE60016629T2 (tr)
EA (1) EA200200596A1 (tr)
EE (1) EE200200358A (tr)
ES (1) ES2231292T3 (tr)
GB (1) GB9930570D0 (tr)
GT (1) GT200000221A (tr)
HU (1) HUP0204585A3 (tr)
IL (1) IL149372A0 (tr)
IS (1) IS6363A (tr)
MA (1) MA26858A1 (tr)
MX (1) MXPA02006315A (tr)
NO (1) NO20023058L (tr)
OA (1) OA12125A (tr)
PA (1) PA8508301A1 (tr)
PE (1) PE20010951A1 (tr)
PL (1) PL357512A1 (tr)
SK (1) SK8102002A3 (tr)
TN (1) TNSN00250A1 (tr)
TR (1) TR200201642T2 (tr)
WO (1) WO2001047901A1 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
US6716861B2 (en) 2000-12-21 2004-04-06 Pfizer, Inc. 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
GB0031321D0 (en) * 2000-12-21 2001-02-07 Pfizer Ltd Treatment
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
GB0108097D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6821972B2 (en) 2001-03-30 2004-11-23 Pfizer Inc. 3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
ES2326119T3 (es) 2003-04-29 2009-10-01 Pfizer Inc. 5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
UA118278C2 (uk) 2014-01-10 2018-12-26 Глаксосмітклайн Інтеллектьюел Проперті (№ 2) Лімітед Гідроксиформамідні похідні та їх застосування
CN108530378B (zh) * 2018-05-29 2021-09-14 济南大学 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法
CN108721282B (zh) * 2018-07-13 2022-02-15 南京市儿童医院 Uk383367在制备用于减轻肾纤维化相关病症的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031892A1 (fr) * 1996-03-01 1997-09-04 Sankyo Company, Limited Derives d'acide hydroxamique
CA2323208A1 (en) * 1998-03-10 1999-09-16 James M. Samanen Vitronectin receptor antagonists

Also Published As

Publication number Publication date
DE60016629T2 (de) 2005-12-08
KR20020067570A (ko) 2002-08-22
NO20023058D0 (no) 2002-06-24
CO5261622A1 (es) 2003-03-31
HUP0204585A3 (en) 2006-01-30
CA2395186C (en) 2006-03-28
AR031085A1 (es) 2003-09-10
NO20023058L (no) 2002-08-23
CN1423638A (zh) 2003-06-11
JP2003519133A (ja) 2003-06-17
HUP0204585A2 (hu) 2003-04-28
GT200000221A (es) 2002-06-14
SK8102002A3 (en) 2003-09-11
CA2395186A1 (en) 2001-07-05
AU1875601A (en) 2001-07-09
EP1240152A1 (en) 2002-09-18
TNSN00250A1 (fr) 2002-05-30
EA200200596A1 (ru) 2002-12-26
WO2001047901A1 (en) 2001-07-05
MXPA02006315A (es) 2002-11-29
GB9930570D0 (en) 2000-02-16
IL149372A0 (en) 2002-11-10
EE200200358A (et) 2003-10-15
PE20010951A1 (es) 2001-09-24
PL357512A1 (en) 2004-07-26
AP2002002554A0 (en) 2002-06-30
BR0016717A (pt) 2002-09-03
MA26858A1 (fr) 2004-12-20
BG106866A (bg) 2003-03-31
IS6363A (is) 2002-04-26
ATE284393T1 (de) 2004-12-15
DE60016629D1 (de) 2005-01-13
PA8508301A1 (es) 2002-08-26
OA12125A (en) 2006-05-05
EP1240152B1 (en) 2004-12-08
ES2231292T3 (es) 2005-05-16

Similar Documents

Publication Publication Date Title
TR200201642T2 (tr) Prokollajen C-Proteinaz inhibitörleri olarak yararlı olan OX (ADI) azolil-hidroksamik asitler.
DK0931788T3 (da) Metalloproteasehæmmere
ATE270817T1 (de) Fungizide
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
MXPA02011977A (es) Herbicidas de piridina sustituidas.
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
ATE235462T1 (de) Metalloproteinase-inhibitoren
NZ512292A (en) Sulfonamide hydroxamates that inhibit procollagen C- proteinase
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
ATE258930T1 (de) Dihydrobenzifurane
TR199700206A2 (tr) Floralkil- ve floralkoksi ikame edilmis heterosiklik bradikinin-antagonistleri, bunlarin imal edilmesine mahsus usul ve bunlarin kullanilmalari.
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
MY128164A (en) Compounds
TR200200745T2 (tr) Fenilasetik asit türevleri için proses.
TR200100133T2 (tr) FKBP İnhibitörleri
ATE277018T1 (de) 3,4-dihydrochinolin-derivative als stickstoffmonoxid-synthase (nos) inhibitoren
AR027349A1 (es) Derivados de amidas heterociclicas
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
AR028537A1 (es) Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
AR024797A1 (es) Forma cristalina iii de la n-(4-(5-dimetilaminonaftalen-1-sulfonilamino)fenil)-3-hidroxi-2,2-dimetilpropionamida
EE200000603A (et) Uudsed ühendid